Catalepsy Produced by Long-Acting Neuroleptics, Fluphenazine Enanthate and Fluphenazine Decanoate, in Mice

Pharmacology ◽  
1982 ◽  
Vol 24 (3) ◽  
pp. 147-155 ◽  
Author(s):  
Katsushi Yamada ◽  
Tatsuo Furukawa
Keyword(s):  
Fluphenazine Decanoate ◽  
Fluphenazine Enanthate ◽  
Long Acting

Long-acting injectable antipsychotic agents

1979 ◽  
Vol 17 (11) ◽  
pp. 41-43
Keyword(s):  
Antipsychotic Agents ◽  
Fluphenazine Decanoate ◽  
Fluphenazine Enanthate ◽  
Long Acting ◽  
Flupenthixol Decanoate

Five long-acting injectable antipsychotic agents (neuroleptics) are available. They are fluphenazine enanthate (Moditen enanthate),1 fluphenazine decanoate (Modecate),2 flupenthixol decanoate (Depixol), cis-clopenthixol decanoate (Clopixol) and fluspirilene (Redeptin).3 Their therapeutic and unwanted effects are broadly similar to those of their oral forms. Nevertheless, injectable preparations have distinct advantages as well as problems.

The Side-Effects of Fluphenazine Decanoate

1973 ◽  
Vol 123 (576) ◽  
pp. 519-522 ◽  
Author(s):  
D. A. W. Johnson
Keyword(s):  
Side Effects ◽  
Clinical Situation ◽  
Fluphenazine Decanoate ◽  
Clinical Control ◽  
Hyper Sensitivity ◽  
Fluphenazine Enanthate ◽  
Extrapyramidal Effects ◽  
Low Incidence ◽  
Long Acting ◽  
Dose Dependent

The unwanted effects of the phenothiazines can be divided into two categories; those effects which represent the pharmacodynamic actions of a particular drug and occur as a function of dosage and individual susceptibility; and the hyper-sensitivity reactions (Shepherd et al., 1968). This latter group of side-effects is relatively rare, and there is no suggestion in the literature that they occur more frequently with the injectable long-acting phenothiazines (LAP) than with the oral forms. With the first available long-acting phenothiazine (fluphenazine enanthate) motor side-effects were frequently observed, particularly during the first few days after injection (Millar and Daniel, 1967; Lowther, 1969; Malm, 1970). Initial studies have suggested that fluphenazine decanoate is less likely to produce these unwanted extrapyramidal effects (Neal and Imlah, 1968; Ayd, 1970). So far, however, no study has attempted to make a quantitative evaluation of the problem of side-effects in the clinical situation of longterm medication. Since both the therapeutic efficacy and the unwanted extra-pyramidal side-effects are dose-dependent, it is meaningless to measure the incidence of side-effects without also recording the therapeutic gain: a low incidence of side-effects might only reflect a non-therapeutic dose of medication. Further, any such study should be continued for at least two months after the last reduction in dosage, as it is well recognized that loss of clinical control may be postponed for many weeks after phenothiazines have been discontinued.

A Controlled Trial of Fluphenazine Enanthate in Hospitalized Chronic Schizophrenics

1968 ◽  
Vol 114 (512) ◽  
pp. 837-841 ◽  
Author(s):  
Ijaz Haider
Keyword(s):  
Controlled Trial ◽  
Chronic Schizophrenics ◽  
Schizophrenic Patients ◽  
Fluphenazine Enanthate ◽  
Prescribed Medicines ◽  
Long Acting

The need for a long-acting phenothiazine has been long recognized, especially since it has been shown (Parkeset al., 1962; Rentonet al., 1963; Kline, 1964; Willcoxet al., 1965; Wilson and Enoch, 1967) that a high proportion of schizophrenic patients do not take their prescribed medicines.

Why a Long-Acting Neuroleptic? Fluphenazine Decanoate

1971 ◽  
Vol 12 (1) ◽  
pp. 56-60 ◽  
Author(s):  
Michael L. Grozier
Keyword(s):  
Fluphenazine Decanoate ◽  
Long Acting

Plasma Levels of Fluphenazine Decanoate

1988 ◽  
Vol 153 (3) ◽  
pp. 382-384 ◽  
Author(s):  
Som D. Soni ◽  
David Wiles ◽  
A. A. Schiff ◽  
J. S. Bamrah
Keyword(s):  
Maintenance Therapy ◽  
Injection Site ◽  
Plasma Levels ◽  
Muscular Exercise ◽  
Blood Levels ◽  
Fluphenazine Decanoate ◽  
Physicochemical Composition ◽  
Depot Neuroleptics ◽  
Long Acting

Depot neuroleptics are now commonly used for maintenance therapy of schizophrenia. Their physicochemical composition makes them ideal for such use because they are long-acting and show stable blood levels for prolonged periods. Their absorption from the site of injection may, however, be affected by local muscle factors. This paper describes three such factors in relation to fluphenazine decanoate: varying the site of injection; massage of the injection site; and effects of muscular exercise. Our results suggest that fluphenazine pharmacokinetics are not significantly affected by any of these factors.

Sign in / Sign up

Export Citation Format

Share Document